Application progress of recombinant human endostatin in the treatment of head and neck cancer
The main treatment of head and neck cancer is comprehensive sequential treatment, but the 5-year overall survival rate is less than 50%. Strategies to further improve the curative effect of head and neck cancer are urgently needed in the clinic. Recombinant human vascular endostatin is an antiangiog...
| 發表在: | 口腔疾病防治 |
|---|---|
| Main Authors: | , |
| 格式: | Article |
| 語言: | 中文 |
| 出版: |
Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases
2020-04-01
|
| 主題: | |
| 在線閱讀: | http://www.kqjbfz.com/CN/10.12016/j.issn.2096-1456.2020.04.012 |